Navigation Links
SemBioSys announces second quarter 2008 financial and operational results
Date:8/5/2008

- 437,012 50,110 874,024

Contract research - 22,395 - 128,171

Product sales 62,207 - 222,124 -

------------ ------------ ------------ ------------

62,207 459,407 272,234 1,002,195

Expenses

Research and

development 3,357,683 1,924,745 6,151,786 3,668,717

General and

administration 1,666,323 1,086,766 3,061,598 2,110,477

Intellectual property

costs 504,690 307,414 847,020 835,663

Business development 155,522 404,434 315,152 713,909

Sales and marketing 96,621 - 249,781 -

Cost of products sold 45,534 - 317,279 -

Stock-based

compensation 175,947 186,654 355,850 365,704

Amortization 580,733 241,887 1,074,567 469,945

Cost recoveries (40,795) (105,177) (573,164) (174,284)

------------ ------------ ------------ ------------

6,542,258 4,046,723 11,799,869 7,990,131

------------ ------------ ------------ ------------

Loss before the

undernoted (6,480,051) (3,587,316) (11,527,635) (6,987,936)

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Interest income 96,649 262,962 267,507 475,195

Interest expense (43,412) (52,570) (105,076) (110,543)

Loss on sale of

property and

equipment - (1,483) - (1,483)

Foreign exchange

gain (lo
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
2. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
3. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
4. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
5. SemBioSys announces first quarter 2008 financial and operational results
6. SemBioSys receives milestone payments from AVAC Ltd.
7. SemBioSys initiates toxicology study for safflower-produced insulin
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
10. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
11. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email: